🧬 OpenCRISPR-1: The world's first AI-generated and open gene editor

🧬 OpenCRISPR-1: The world's first AI-generated and open gene editor

The OpenCRISPR initiative aims to democratize gene technology and accelerate the development of customized genetic treatments. By making this technology available, Profluent hopes to increase access and reduce the costs of gene editing treatments.

Mathias Sundin
Mathias Sundin

Share this story!

  • Profluent has developed OpenCRISPR-1, an AI-generated gene editor that is free to license for both research and commercial use.
  • The OpenCRISPR initiative aims to democratize gene technology and accelerate the development of customized genetic treatments.
  • By making this technology available, Profluent hopes to increase access and reduce the costs of gene editing treatments.

AI creates new possibilities in genetic engineering

Profluent, a company that develops protein design with AI, has launched OpenCRISPR-1, the world’s first open and AI-generated gene editor. This tool, consisting of a Cas9-like protein and guide RNA, has been entirely developed with the help of Profluent's large language models (LLM).

During the development process, Profluent’s AI learned to understand sequences and biological context on a large scale, enabling the creation of millions of different CRISPR-like proteins that do not occur in nature.

This broadens the spectrum of known CRISPR families in a way that would not be possible with traditional protein development methods.

Unlocking the potential for tailored care

Profluent aims to make CRISPR-based medicine more accessible to more patients and for a broader range of diseases. The unique ability of AI to create gene editing systems from scratch is key to this progress. By increasing access and reducing the costs of such treatments, we may see an acceleration in the treatment of diseases currently considered incurable.

Ali Madani, co-founder and CEO of Profluent, describes the launch of OpenCRISPR as a "scientific moonshot." By opening its technology to researchers and commercial actors worldwide, Profluent hopes to stimulate innovation and democratization in the field of gene editing.

Profluent encourages the gene editing community to test OpenCRISPR-1 and collaborate to optimize its features for specific applications. This openness and willingness to collaborate are intended to facilitate faster progress in genetic medicine.

WALL-Y
WALL-Y is an AI bot created in ChatGPT. Learn more about WALL-Y and how we develop her. You can find her news here.
You can chat with WALL-Y GPT about this news article and fact-based optimism (requires the paid version of ChatGPT.)

❤️ Health Tech🧠 Artificial IntelligenceCRISPR

You might also like

Matt Ridley 5 min read

💉 Matt Ridley: The unexpected history and miraculous success of vaccines

At a time when the miraculous success of vaccines has transformed the battle against the pandemic it is fitting to recall the general idea, and unexpected history, behind vaccination, writes Matt Ridley, bestselling author of The Rational Optimist and How Innovation Works.

Mathias Sundin 5 min read

🎵 Now there's a ChatGPT for making music (my three-year-old son and I made an opera)

I sing out of tune and can't play any instrument. My son is three years old. Yet, we have made an opera together. This has been made possible thanks to the latest developments in generative AI.

Mathias Sundin 3 min read

💡 Musings of the Angry Optimist: Is a revolution underway?

Usually, when writing an opinion piece, it carries a thesis or a message. Not this one. It ends with an open question. That question is based on the notion that something big is underway. Something revolutionary.